EntryPoint Capital LLC Reduces Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

EntryPoint Capital LLC decreased its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 15.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,924 shares of the biopharmaceutical company’s stock after selling 537 shares during the period. EntryPoint Capital LLC’s holdings in Agios Pharmaceuticals were worth $85,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of AGIO. Assenagon Asset Management S.A. lifted its stake in Agios Pharmaceuticals by 800.5% in the first quarter. Assenagon Asset Management S.A. now owns 454,801 shares of the biopharmaceutical company’s stock valued at $13,298,000 after purchasing an additional 404,297 shares during the last quarter. Norges Bank purchased a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at $6,826,000. Frazier Life Sciences Management L.P. raised its stake in shares of Agios Pharmaceuticals by 79.2% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 523,166 shares of the biopharmaceutical company’s stock valued at $11,651,000 after purchasing an additional 231,164 shares during the period. Armistice Capital LLC lifted its holdings in Agios Pharmaceuticals by 6.0% during the 4th quarter. Armistice Capital LLC now owns 3,524,000 shares of the biopharmaceutical company’s stock worth $78,479,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Agios Pharmaceuticals by 5.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,596,764 shares of the biopharmaceutical company’s stock worth $57,832,000 after purchasing an additional 137,873 shares during the period.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on AGIO shares. The Goldman Sachs Group upped their price target on Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a “neutral” rating in a research report on Tuesday, June 4th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $46.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, June 13th. Royal Bank of Canada increased their target price on shares of Agios Pharmaceuticals from $44.00 to $53.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 4th. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Monday, June 17th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Agios Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $50.67.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO traded down $0.57 during trading hours on Friday, reaching $47.93. The company’s stock had a trading volume of 106,424 shares, compared to its average volume of 794,780. The firm has a 50-day simple moving average of $42.92 and a 200-day simple moving average of $33.52. Agios Pharmaceuticals, Inc. has a 1 year low of $19.80 and a 1 year high of $50.35.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) EPS for the quarter, topping analysts’ consensus estimates of ($1.65) by $0.20. The company had revenue of $8.19 million for the quarter, compared to analysts’ expectations of $8.37 million. Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative return on equity of 41.41%. The firm’s revenue was up 46.0% compared to the same quarter last year. During the same quarter last year, the company earned ($1.47) EPS. Research analysts anticipate that Agios Pharmaceuticals, Inc. will post -2.15 earnings per share for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.